Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Sarepta’s Gene Therapy Elevidys Casting Doubt On A Popular DMD Endpoint?

Executive Summary

Sponsors don’t seem worried that US FDA will become skeptical of the North Star Ambulatory Assessment (NSAA) because Sarepta says it was not sensitive enough to detect patient changes in the confirmatory trial for its DMD gene therapy Elevidys.

You may also be interested in...



Accelerated Approval Now Starting Point For Gene Therapy Development, US FDA’s Marks Says

Expedited approval pathway had been a secondary option when traditional approval was not possible, but the CBER director wants surrogate endpoints increasingly considered from the beginning, especially with pediatric rare disease gene therapies.

Sarepta Confident Of Full US Approval For Duchenne Gene Therapy By Mid-2024

Elevidys has enjoyed a strong launch, despite being restricted to a small number of Duchenne patients. Sarepta is hoping the US regulator will overlook trial problems and allow its expanded use.

Finance Watch: Though Flush With Cash, Theseus Seeks Alternatives, Gets Two Quick Offers

Restructuring Edition: OrbiMed/Foresite and Concentra responded quickly after Theseus implemented a 72% workforce reduction and began a search for strategic alternatives despite having $225.4m in cash. REGENXBIO, Novavax and Lyell also revealed job cuts despite large cash stockpiles.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel